







EVALUATION OF BARICITINIB IN PEDIATRIC PATIENTS WITH ALOPECIA AREATA


Background and importance

Alopecia Areata:


-  Immune-mediated disorder
-  Global prevalence: 2%, higher in children
-  No curative treatment

Baricitinib:

-  JAK1/JAK2 inhibitor
-  Aproved and financed for adults with SALT \geq 50% and no response to standard of care treatment
-  Treatment response: SALT \leq 20% after 36 weeks

 The SALT score is the sum of the percentage of each scalp region (top, right, left, and back), multiplied by its respective weight, ranging from 0 (no hair loss) to 100 (total scalp hair loss).

Aim and objective

 To evaluate off-label **baricitinib** in **children** with severe and **refractory alopecia areata** in a third-level pediatric hospital.


Material and Methods

Patients' clinical history

Age

Treatment time


Minimum 1 followed-up visit




Baseline and progress



**SALT
Severity of Alopecia Tool score**



Side effects



Patients' feedback

Results


Patients' characteristics

| | |
|------------------------|------------------------|
| Sex | 7 boys /10 girls |
| Average age | 12.2 years (SD 2.75) |
| Average treatment time | 36,91 weeks (SD 13.23) |
| One follow-up visit | 76,47% |

Safety


Well-tolerated

42.86% patients with abnormal laboratory results



Cholesterol, LDH, ALP, GGT

Patients' characteristics




 Achieved goal

 Insufficient improvement

 No regrowth

 Worsening of condition

Conclusion and Relevance



Debatable results in pediatric population



Satisfactory results in half of the patients, and full recovery in certain cases

